Inflection Year for Psychedelics: A Sector Map for 2026

Psychedelic medicine faces a 2026 inflection point, with multiple companies approaching Phase 3 readouts and potential FDA submissions. The piece maps major players and how their drug design and delivery differ, including Compass Pathways with synthetic psilocybin (COMP360) targeting a Q4 2026 rolling NDA, Definium Therapeutics with LSD-based DT120 expecting several 2026 topline events, and AtaiBeckley advancing intranasal mebufotenin (BPL-003) toward Phase 3 trials. GH Research is highlighted for inhaled mebufotenin (5-MeO-DMT) with earlier Phase 2b results and a lifted clinical hold, affecting its Phase 3 timeline. A central commercialization thesis is that efficacy alone is not enough: session duration, clinic monitoring requirements similar to esketamine REMS workflows, whether psychotherapy is included, and dosing frequency will determine whether treatments can be operationalized and reimbursed at scale.